The National Cancer Institute awarded a purchase order to Oxford Nanopore Technologies, Inc., for one PromethION 2 Integrated long-read sequencing platform, including installation, calibration, standard support plan, and initial user training, valued at $66,380 and issued on September 24, 2026. No set-aside was used. Performance occurs at Bethesda, Maryland, with delivery and installation required within four to twelve weeks of award. The procurement originated from a Department of the Interior Interior Business Center competitive RFQ issued August 26, 2026, with quotations due September 2, 2026. The solicitation applied a Women-Owned Small Business set-aside, though the award carries no set-aside designation. Brand-name justification restricted competition to Oxford Nanopore based on compatibility with the CCR Genomics Core's existing validated workflows, flow cells, chemistries, and software pipelines; market research confirmed no alternative sequencing platform provides equivalent integrated compute capability while maintaining existing laboratory infrastructure. Contract completion is due January 23, 2027.